VD's Model Portfolio & Discussion Thread Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Cytokine1 who wrote (4204)	2/27/1998 11:40:00 AM
From: Vector1	Read Replies (1) of 9719

Cyto, CLTR is up big again. Piper issued a report today with this conclusion: Conclusion We believe that Coulter's current market value of only $275 million does not reflect Bexxar's late-stage of development or market opportunity in the treatment of non-Hodgkin's lymphoma. We forecast that a major partnership and pivotal trial results relating to Bexxar will underscore the product's potential and lead Coulter's stock to our $31 one-year target price. This price target is based on a 30 multiple of our fully taxed year 2001 EPS estimate of $1.90, discounted back at a 35% rate. We recommend that investors Buy Coulter in anticipation of a watershed year for the Company.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next